Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)

Disease Sites:

Not Available

Staging:

Phase III

Age Group:

Adults

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Luckenbaugh, Amy

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

05-31-2024

Trial Type:

Treatment

Protocol ID:

VICC-DDURO24101

National Clinical Trial ID:

NCT06111235

Related Internal Documents:

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available